Literature DB >> 8154632

Comparison of the bronchodilator response to albuterol administered by the OptiHaler, the AeroChamber, or by metered dose inhaler alone.

H S Nelson1, D T Loffert.   

Abstract

Eighteen subjects with moderate asthma participated in this double-blind study comparing the bronchodilator response to albuterol or placebo used in conjunction with three inhalation devices; the metered dose inhaler (MDI) actuator alone, the AeroChamber, and the OptiHaler. The principal comparison was the increase in FEV1 over 30 minutes. Also recorded were heart rate, time required to use each device, and patient acceptance of each device. There was a large bronchodilator response with albuterol with each of the devices, but there was no difference in the promptness or the magnitude of the bronchodilator response among the three devices. There was a small but statistically significant increase in heart rate which did not differ among devices. Subject ratings of acceptability were MDI alone best, followed by OptiHaler, then AeroChamber. We conclude (1) the bronchodilator response obtained with use of the MDI alone, the AeroChamber and OptiHaler were not significantly different; (2) patients, as a group, found the MDI required less time to use and they favored it over either spacer; (3) while in subjects employing good MDI technique, the addition of either an AeroChamber or an OptiHaler did not improve bronchodilator response. Spacers may have a role in those with poor inhaler technique or in conjunction with inhaled corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8154632

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  2 in total

Review 1.  The economic aspects of drug delivery in asthma.

Authors:  R J Massie; C M Mellis
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

2.  Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation.

Authors:  Anton Drollmann; Ruediger Nave; Volker W Steinijans; Eugen Baumgärtner; Thomas D Bethke
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.